BTK Inhibition in Lymphomas: A Focus on Frontline Therapy for DLBCL
Released On
January 28, 2025
Expires On
January 28, 2026
Media Type
Internet
Completion Time
60 minutes
Specialty
Hematology-Oncology
Topic(s)
Lymphoma
CME INFO
Jointly provided by Partners for Advancing Clinical Education (PACE) and PlatformQ Health Education, LLC (PQHE).
Acknowledgement
This activity is supported by an independent educational grant from AstraZeneca Pharmaceuticals.
Date of Release/Expiration
This activity was released on January 28, 2025 and is valid until January 28, 2026. Requests for credit must be made no later than January 28, 2026.
Credit Available
- Physicians - maximum of 1.0 AMA PRA Category 1 Credit™
All other healthcare professionals completing this course will be issued a statement of participation.
Target Audience
Hematologic oncologists, hematologists, medical oncologists, oncology advanced practice providers (NPs and PAs), oncology nurses, and other clinicians involved in the treatment and management of patients with DLBCL.
Program Overview
As ongoing advances continue to change the treatment landscape for difficult‐to-treat diffuse large B‐cell lymphoma (DLBCL), it is imperative that clinicians stay up to date with the most recent safety and efficacy data for emerging treatment options such as BTK inhibitors and when to consider these therapies for their patients.
To help realize the potential of BTK inhibitors in DLBCL, join a panel of DLBCL experts discuss incorporating these therapies in the frontline setting, management of associated side effects, and personalization of treatment plans. Panelists will also discuss the insights from a practice patterns survey of community-based clinicians that manage their patients with DLBCL with BTK inhibitors.
Educational Objectives
After completing this activity, the participant should be better able to:
- Outline the importance of appropriate frontline treatment selection and the rationale for the use of BTK inhibitors in earlier treatment settings for DLBCL
- Evaluate clinical data for emerging targeted approaches using BTK inhibitors in the newly diagnosed setting for patients with DLBCL
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and PlatformQ Health Education, LLC. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Education
PACE designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Estimated Time to Complete
This activity should take approximately 60 minutes to complete.
Instructions to Receive Credit
In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a score of 75% on the post-test.
Hardware/Software Requirements
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.
Fee Information & Refund/Cancellation Policy
There is no fee for this educational activity.
Faculty and Disclosure of Conflicts of Interest
PACE requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:
The PACE planners and others have no relevant financial relationship(s) to disclose with ineligible companies. The PlatformQ Health Education, LLC planners and others have no relevant financial relationship(s) to disclose with ineligible companies.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Contact Information
Accreditaiton Support
For information about the accreditation of this activity, please visit https://partnersed.com.
Technical Support
For any technical issues or issues with your CME Certificate, please contact MedLive at 877-394-1306 or at [email protected].
<2>Medlive Privacy Policy2>